Scientists at the University of Tubingen and the German Centre for Infection Research (DZIF) discovered that Staphylococcus lugdunensis in our nose produces the antibiotic.
As tests on mice have shown, the substance which has been named Lugdunin is able to combat multiresistant pathogens, where many classic antibiotics have become ineffective.
Infections caused by antibiotic-resistant bacteria - like the pathogen Staphylococcus aureus (MRSA) which colonises on human skin - are among the leading causes of death worldwide.
The natural habitat of harmful Staphylococcus bacteria is the human nasal cavity.
"Normally antibiotics are formed only by soil bacteria and fungi. The notion that human microflora may also be a source of antimicrobial agents is a new discovery," said Professor Andreas Peschel, from Interfaculty Institute for Microbiology and Infection Medicine Tubingen (IMIT).
In future studies, scientists will examine whether Lugdunin could actually be used in therapy. One potential use is introducing harmless Lugdunin-forming bacteria to patients at risk from MRSA as a preventative measure.
Researchers closely examined the structure of Lugdunin and discovered that it consists of a previously unknown ring structure of protein blocks and thus establishes a new class of materials.
As many of the pathogens are part of human microflora on skin and mucous membranes, they cannot be avoided.
Particularly for patients with serious underlying illnesses and weakened immune systems they represent a high risk - these patients are easy prey for the pathogens.
The research was published in the journal Nature.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
